Last update 21 Nov 2024
23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine |
Synonyms 23-Valent Pneumococcal Polysaccharide Vaccine, 23价肺炎球菌多糖疫苗（成都生物制品研究所）, 惠益康 |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (24 Apr 2006), |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)Immunogenicity and Safety of Quadrivalent Influenza Vaccine Combined Immunization With 23-valent Pneumococcal Polysaccharide Vaccine in the Elderly Aged 60 Years and Above
A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Wuhan) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)
A randomized, controlled, multi-center clinical study to evaluate the immunogenicity and safety of the new coronavirus inactivated vaccine and the 23-valent pneumococcal polysaccharide vaccine and the quadrivalent influenza virus split vaccine at the same time
100 Clinical Results associated with 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)
Login to view more data
100 Translational Medicine associated with 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)
Login to view more data
100 Patents (Medical) associated with 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)
Login to view more data
1
Literatures (Medical) associated with 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)PLOS ONEQ3 · CROSS-FIELD
Correction: Limited indirect effects of an infant pneumococcal vaccination program in an aging population
Q3 · CROSS-FIELD
OA
Author: Perniciaro, Stephanie ; Imöhl, Matthias ; van der Linden, Mark
100 Deals associated with 23-valent pneumococcal polysaccharide vaccine(Chengdu Institute of Biological Products)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Pneumonia, Bacterial | CN | 24 Apr 2006 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free